<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03396146</url>
  </required_header>
  <id_info>
    <org_study_id>K160403J</org_study_id>
    <secondary_id>2017-A00612-51</secondary_id>
    <nct_id>NCT03396146</nct_id>
  </id_info>
  <brief_title>Assay for the Pancreatic Polypeptide: an Help for Clinical Practice Guidelines in Classification of the Diabetes</brief_title>
  <acronym>DIAPP</acronym>
  <official_title>Assay for the Pancreatic Polypeptide: an Help for Clinical Practice Guidelines in Classification of the Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cochin Hospital's Hormonology Laboratory</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate global endocrine function within type 1 and type 3c
      diabetic patients, helping pancreatic polypeptide measurement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All diabetes are the result of endrocrine deficiency. The endocrine deficiency may be
      absolute, as in type 1 diabetes, considered as an elective and exclusive attack of pancreatic
      Beta cell, or it could be relative, as un type 2 diabetes.

      More rarely, diabetes fit into a broader context of pancreatic failure, with diffuse
      involvement of the exocrine and endocrine function, suggesting an impairment of the whole
      endocrine secretion of the pancreas, affecting the entire islet of Langerhans, such as in
      type 3c diabetes, whose prototypes are total pancreatectomy, chronic alcoholic pancreatitis,
      cystic fibrosis.

      The diagnostic of type 3c diabetes is not always obvious, with several clinical
      presentations, without biological specific disease tag. Moreover, it also appears that the
      common form of diabetes, type 1 and type 2, may be associated with an exocrine function
      deficit and with a decrease of the pancreatic volume correlated with exocrine function
      abnormalities, and a decrease of insulin secretion capacity. The consequences of a spread of
      the disease beyond the Beta cells remain uncertain, but they could be linked, as in type 3c
      diabetes, with severe form of hypoglycaemia, due to glucagon deficiency, or nutritional
      deficiency due to the exocrine deficiency.

      The pancreatic polypeptide belongs to the neuropeptide Y family, it is produced by the
      endocrine pancreatic F cells, located in the hook and the head of the pancreas. Food intake
      stimulates its secretion. The role of the pancreatic polypeptide in human is uncertain.

      Investigators propose to study the pancreatic polypeptide in type 1 and type 3c diabetes
      before and after a mixed meal in order to study the other endocrine functions of the islet of
      Langerhans, to evaluate the possibility, or not, of a more diffuse pancreatic involvement in
      type 1 diabetes, considered as an elective pathology of the pancreatic Beta cell.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of pancreatic polypeptide for calculating the area under the curve</measure>
    <time_frame>1 day</time_frame>
    <description>physiological parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of C-peptide levels</measure>
    <time_frame>1 day</time_frame>
    <description>physiological parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of fecal elastase level</measure>
    <time_frame>at inclusion</time_frame>
    <description>physiological parameters</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Type1diabetes</condition>
  <arm_group>
    <arm_group_label>Type1diabetes with exocrine pancreatic function insufficiency</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 ml total blood tubes volume Fecal sample</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type1diabetes without exocrine pancreatic function insuficienc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 ml total blood tubes volume Fecal sample</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 3c diabetes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12 ml total blood tubes volume Fecal sample</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>12 ml total blood tubes volume</intervention_name>
    <description>12 ml total blood tubes at -10, 0, +30, +60, + 90, + 120 minutes before and after a mixed meal</description>
    <arm_group_label>Type1diabetes with exocrine pancreatic function insufficiency</arm_group_label>
    <arm_group_label>Type1diabetes without exocrine pancreatic function insuficienc</arm_group_label>
    <arm_group_label>Type 3c diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fecal sample</intervention_name>
    <description>Fecal sample at inclusion</description>
    <arm_group_label>Type1diabetes with exocrine pancreatic function insufficiency</arm_group_label>
    <arm_group_label>Type1diabetes without exocrine pancreatic function insuficienc</arm_group_label>
    <arm_group_label>Type 3c diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18 years or older

          -  Patients with type 1 diabetes with anti-GAD and / or IA2 and / or Znt8 positive
             antibodies, or characteristic clinical history, with and without exocrine deficiency
             (*)

          -  Patients with chronic alcoholic pancreatitis or cystic fibrosis origin (type 3c
             diabetes), complicated with diabetes defined by HbA1c&gt; 6.5% or treated with oral
             anti-diabetic and / or insulin

          -  Patients who have given informed and written consent to participate in research

          -  Patients affiliated to a social security scheme (*): The exocrine deficiency is
             defined by an assay of fecal elastase:

          -  without deficit of exocrine function = fecal elastase = /&gt; 100 μg / g

          -  with deficit of exocrine function = fecal elastase &lt;100 μg / g

        Exclusion Criteria:

          -  Pregnancy

          -  Severe renal impairment (eDFG &lt;45 mL / min / 1.73 m²)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Etienne LARGER, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Léa DEHGHANI, MD, PhD</last_name>
    <phone>+ 33 1 58 41 39 63</phone>
    <email>lea.dehghani@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christelle AUGER</last_name>
    <phone>+ 33 1 58 41 11 86</phone>
    <email>christelle.auger@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Léa DEHGHANI, MD, PhD</last_name>
      <phone>+ 33 1 58 41 39 63</phone>
      <email>lea.dehghani@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Larger E, Philippe MF, Barbot-Trystram L, Radu A, Rotariu M, Nobécourt E, Boitard C. Pancreatic exocrine function in patients with diabetes. Diabet Med. 2012 Aug;29(8):1047-54. doi: 10.1111/j.1464-5491.2012.03597.x.</citation>
    <PMID>22273174</PMID>
  </reference>
  <reference>
    <citation>Philippe MF, Benabadji S, Barbot-Trystram L, Vadrot D, Boitard C, Larger E. Pancreatic volume and endocrine and exocrine functions in patients with diabetes. Pancreas. 2011 Apr;40(3):359-63. doi: 10.1097/MPA.0b013e3182072032.</citation>
    <PMID>21283038</PMID>
  </reference>
  <reference>
    <citation>Rickels MR, Bellin M, Toledo FG, Robertson RP, Andersen DK, Chari ST, Brand R, Frulloni L, Anderson MA, Whitcomb DC; PancreasFest Recommendation Conference Participants. Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: recommendations from PancreasFest 2012. Pancreatology. 2013 Jul-Aug;13(4):336-42. doi: 10.1016/j.pan.2013.05.002. Epub 2013 May 17.</citation>
    <PMID>23890130</PMID>
  </reference>
  <reference>
    <citation>Khandekar N, Berning BA, Sainsbury A, Lin S. The role of pancreatic polypeptide in the regulation of energy homeostasis. Mol Cell Endocrinol. 2015 Dec 15;418 Pt 1:33-41. doi: 10.1016/j.mce.2015.06.028. Epub 2015 Jun 27. Review.</citation>
    <PMID>26123585</PMID>
  </reference>
  <reference>
    <citation>Hennig R, Kekis PB, Friess H, Adrian TE, Büchler MW. Pancreatic polypeptide in pancreatitis. Peptides. 2002 Feb;23(2):331-8. Review.</citation>
    <PMID>11825647</PMID>
  </reference>
  <reference>
    <citation>Wang X, Zielinski MC, Misawa R, Wen P, Wang TY, Wang CZ, Witkowski P, Hara M. Quantitative analysis of pancreatic polypeptide cell distribution in the human pancreas. PLoS One. 2013;8(1):e55501. doi: 10.1371/journal.pone.0055501. Epub 2013 Jan 31.</citation>
    <PMID>23383206</PMID>
  </reference>
  <reference>
    <citation>Simonian HP, Kresge KM, Boden GH, Parkman HP. Differential effects of sham feeding and meal ingestion on ghrelin and pancreatic polypeptide levels: evidence for vagal efferent stimulation mediating ghrelin release. Neurogastroenterol Motil. 2005 Jun;17(3):348-54.</citation>
    <PMID>15916622</PMID>
  </reference>
  <reference>
    <citation>Veedfald S, Plamboeck A, Hartmann B, Svendsen LB, Vilsbøll T, Knop FK, Holst JJ. Pancreatic polypeptide responses to isoglycemic oral and intravenous glucose in humans with and without intact vagal innervation. Peptides. 2015 Sep;71:229-31. doi: 10.1016/j.peptides.2015.07.020. Epub 2015 Jul 26.</citation>
    <PMID>26218807</PMID>
  </reference>
  <reference>
    <citation>Batterham RL, Le Roux CW, Cohen MA, Park AJ, Ellis SM, Patterson M, Frost GS, Ghatei MA, Bloom SR. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab. 2003 Aug;88(8):3989-92.</citation>
    <PMID>12915697</PMID>
  </reference>
  <reference>
    <citation>Brunicardi FC, Chaiken RL, Ryan AS, Seymour NE, Hoffmann JA, Lebovitz HE, Chance RE, Gingerich RL, Andersen DK, Elahi D. Pancreatic polypeptide administration improves abnormal glucose metabolism in patients with chronic pancreatitis. J Clin Endocrinol Metab. 1996 Oct;81(10):3566-72.</citation>
    <PMID>8855802</PMID>
  </reference>
  <reference>
    <citation>Rabiee A, Galiatsatos P, Salas-Carrillo R, Thompson MJ, Andersen DK, Elahi D. Pancreatic polypeptide administration enhances insulin sensitivity and reduces the insulin requirement of patients on insulin pump therapy. J Diabetes Sci Technol. 2011 Nov 1;5(6):1521-8.</citation>
    <PMID>22226275</PMID>
  </reference>
  <reference>
    <citation>Henquin JC, Rahier J. Pancreatic alpha cell mass in European subjects with type 2 diabetes. Diabetologia. 2011 Jul;54(7):1720-5. doi: 10.1007/s00125-011-2118-4. Epub 2011 Apr 5.</citation>
    <PMID>21465328</PMID>
  </reference>
  <reference>
    <citation>Diedisheim M, Mallone R, Boitard C, Larger E. β-cell Mass in Nondiabetic Autoantibody-Positive Subjects: An Analysis Based on the Network for Pancreatic Organ Donors Database. J Clin Endocrinol Metab. 2016 Apr;101(4):1390-7. doi: 10.1210/jc.2015-3756. Epub 2016 Feb 1.</citation>
    <PMID>26829442</PMID>
  </reference>
  <reference>
    <citation>Gerich JE, Langlois M, Noacco C, Karam JH, Forsham PH. Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha cell defect. Science. 1973 Oct 12;182(4108):171-3.</citation>
    <PMID>4581053</PMID>
  </reference>
  <reference>
    <citation>Lund A, Bagger JI, Wewer Albrechtsen NJ, Christensen M, Grøndahl M, Hartmann B, Mathiesen ER, Hansen CP, Storkholm JH, van Hall G, Rehfeld JF, Hornburg D, Meissner F, Mann M, Larsen S, Holst JJ, Vilsbøll T, Knop FK. Evidence of Extrapancreatic Glucagon Secretion in Man. Diabetes. 2016 Mar;65(3):585-97. doi: 10.2337/db15-1541. Epub 2015 Dec 15. Erratum in: Diabetes. 2016 Jun;65(6):1752.</citation>
    <PMID>26672094</PMID>
  </reference>
  <reference>
    <citation>Tiengo A, Bessioud M, Valverde I, Tabbi-Anneni A, Delprato S, Alexandre J, Assan R. Absence of islet alpha cell function in pancreatectomized patients. Diabetologia. 1982 Jan;22(1):25-32.</citation>
    <PMID>6120875</PMID>
  </reference>
  <reference>
    <citation>Haldorsen IS, Ræder H, Vesterhus M, Molven A, Njølstad PR. The role of pancreatic imaging in monogenic diabetes mellitus. Nat Rev Endocrinol. 2011 Nov 29;8(3):148-59. doi: 10.1038/nrendo.2011.197. Review.</citation>
    <PMID>22124438</PMID>
  </reference>
  <reference>
    <citation>Bellanné-Chantelot C, Chauveau D, Gautier JF, Dubois-Laforgue D, Clauin S, Beaufils S, Wilhelm JM, Boitard C, Noël LH, Velho G, Timsit J. Clinical spectrum associated with hepatocyte nuclear factor-1beta mutations. Ann Intern Med. 2004 Apr 6;140(7):510-7.</citation>
    <PMID>15068978</PMID>
  </reference>
  <reference>
    <citation>Andersen BN, Hagen C, Klein HC, Stadil F, Worning H. Correlation between exocrine pancreatic secretion and serum concentration of human pancreatic polypeptide in chronic pancreatitis. Scand J Gastroenterol. 1980;15(6):699-704.</citation>
    <PMID>7209380</PMID>
  </reference>
  <reference>
    <citation>Matsumoto M, Wakasugi H, Ibayashi H. Plasma human pancreatic polypeptide response in chronic pancreatitis. Gastroenterol Jpn. 1982;17(1):25-30.</citation>
    <PMID>7042449</PMID>
  </reference>
  <reference>
    <citation>Vu MK, Vecht J, Eddes EH, Biemond I, Lamers CB, Masclee AA. Antroduodenal motility in chronic pancreatitis: are abnormalities related to exocrine insufficiency? Am J Physiol Gastrointest Liver Physiol. 2000 Mar;278(3):G458-66.</citation>
    <PMID>10712266</PMID>
  </reference>
  <reference>
    <citation>Sobngwi E, Boudou P, Mauvais-Jarvis F, Leblanc H, Velho G, Vexiau P, Porcher R, Hadjadj S, Pratley R, Tataranni PA, Calvo F, Gautier JF. Effect of a diabetic environment in utero on predisposition to type 2 diabetes. Lancet. 2003 May 31;361(9372):1861-5.</citation>
    <PMID>12788573</PMID>
  </reference>
  <reference>
    <citation>Chia CW, Odetunde JO, Kim W, Carlson OD, Ferrucci L, Egan JM. GIP contributes to islet trihormonal abnormalities in type 2 diabetes. J Clin Endocrinol Metab. 2014 Jul;99(7):2477-85. doi: 10.1210/jc.2013-3994. Epub 2014 Apr 8.</citation>
    <PMID>24712564</PMID>
  </reference>
  <reference>
    <citation>Belinova L, Kahleova H, Malinska H, Topolcan O, Vrzalova J, Oliyarnyk O, Kazdova L, Hill M, Pelikanova T. Differential acute postprandial effects of processed meat and isocaloric vegan meals on the gastrointestinal hormone response in subjects suffering from type 2 diabetes and healthy controls: a randomized crossover study. PLoS One. 2014 Sep 15;9(9):e107561. doi: 10.1371/journal.pone.0107561. eCollection 2014.</citation>
    <PMID>25222490</PMID>
  </reference>
  <reference>
    <citation>Hart PA, Baichoo E, Bi Y, Hinton A, Kudva YC, Chari ST. Pancreatic polypeptide response to a mixed meal is blunted in pancreatic head cancer associated with diabetes mellitus. Pancreatology. 2015 Mar-Apr;15(2):162-6. doi: 10.1016/j.pan.2015.02.006. Epub 2015 Feb 24.</citation>
    <PMID>25766398</PMID>
  </reference>
  <reference>
    <citation>Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, Proietto J. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011 Oct 27;365(17):1597-604. doi: 10.1056/NEJMoa1105816.</citation>
    <PMID>22029981</PMID>
  </reference>
  <reference>
    <citation>Nealon WH, Townsend CM Jr, Thompson JC. The time course of beta cell dysfunction in chronic ethanol-induced pancreatitis: a prospective analysis. Surgery. 1988 Dec;104(6):1074-9.</citation>
    <PMID>3057670</PMID>
  </reference>
  <reference>
    <citation>Brunicardi FC, Druck P, Sun YS, Elahi D, Gingerich RL, Andersen DK. Regulation of pancreatic polypeptide secretion in the isolated perfused human pancreas. Am J Surg. 1988 Jan;155(1):63-9.</citation>
    <PMID>3277467</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2017</study_first_submitted>
  <study_first_submitted_qc>January 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2018</study_first_posted>
  <last_update_submitted>March 16, 2018</last_update_submitted>
  <last_update_submitted_qc>March 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic polypeptide</keyword>
  <keyword>Type 1 diabetes</keyword>
  <keyword>Chronic pancreatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Polypeptide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

